Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Andrew L. Coveler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1710-5637; OpenAlex author ID A5060994391. Sources: ClinicalTrials.gov.

Their work

Papers
24 (first author 5, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
120
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 4 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 5 papers · 2026: 4 papers, 1 trial

Papers 24

  1. Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization. Co-author DOI 10.1002/pon.70601↗
  2. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  3. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
  4. Correction: Chang et al. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Cancers 2025, 17, 630. Last author DOI 10.3390/cancers18050789↗
  5. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  6. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … Co-author DOI 10.1016/j.esmoop.2025.105122↗
  7. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  8. Targeting metabolism in pancreatic ductal adenocarcinoma: challenges and insights from the AVENGER 500 trial. First author DOI 10.21037/jgo-2025-61↗
  9. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Last author DOI 10.3390/cancers17040630↗
  10. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  11. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2208470↗
  12. Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002253↗
  13. CT perfusion as a potential biomarker for pancreatic ductal adenocarcinoma during routine staging and restaging. Co-author DOI 10.1007/s00261-022-03638-7↗
  14. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable … Co-author DOI 10.1097/sla.0000000000004669↗
  15. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experienc… Co-author DOI 10.1002/cam4.4257↗
  16. Feasibility of wide detector CT perfusion imaging performed during routine staging and restaging of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-020-02786-y↗
  17. DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001819↗
  18. GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. First author DOI 10.3390/biology10070610↗
  19. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. First author DOI 10.1053/j.seminoncol.2018.05.004↗
  20. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Co-author DOI 10.1080/2162402x.2017.1333210↗
  21. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. First author DOI 10.1080/21645515.2015.1093264↗
  22. Localized Pancreatic Cancer: Multidisciplinary Management. Co-author DOI 10.1200/edbk_160827↗
  23. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Co-author DOI 10.2217/imt.15.113↗
  24. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. First author DOI 10.2147/dddt.s60328↗

Trials 2

  1. Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer Principal investigator NCT07645651↗
  2. Perioperative Therapy for Resectable Pancreatic Cancer Principal investigator NCT00609336↗

Closest collaborators

The 25 strongest of 120 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Eugene Hendifar · 5 shared papers, 2021–2026 · strength 1.22
  2. Elena Gabriela Chiorean · 8 shared papers, 2015–2026 · strength 0.95
  3. David Bing Zhen · 4 shared papers, 2018–2026 · strength 0.62
  4. An Ngo‐Huang · 2 shared papers, 2025–2026 · strength 0.62
  5. Nathan H. Parker · 2 shared papers, 2025–2026 · strength 0.62
  6. Philip J. Chang · 2 shared papers, 2025–2026 · strength 0.62
  7. Gillian K. Gresham · 2 shared papers, 2025–2026 · strength 0.62
  8. Paul E. Oberstein · 2 shared papers, 2025–2026 · strength 0.62
  9. Andrès M.R. Cervantes · 3 shared papers, 2025–2026 · strength 0.57
  10. Elizabeth S. Nakasone · 1 shared paper, 2025 · strength 0.54
  11. Benedito A. Carneiro · 2 shared papers, 2025–2026 · strength 0.41
  12. Devalingam Mahalingam · 2 shared papers, 2025–2026 · strength 0.41
  13. Vaibhav Sahai · 2 shared papers, 2025–2026 · strength 0.41
  14. Mary F. Mulcahy · 2 shared papers, 2025–2026 · strength 0.41
  15. Ludimila L. Cavalcante · 2 shared papers, 2021–2025 · strength 0.38
  16. Anwaar Saeed · 2 shared papers, 2021–2025 · strength 0.38
  17. Venu Gopal Pillarisetty · 3 shared papers, 2017–2023 · strength 0.35
  18. Noelle K. LoConte · 2 shared papers, 2022–2026 · strength 0.33
  19. Carolyn L. Wang · 2 shared papers, 2021–2022 · strength 0.30
  20. Erik V. Soloff · 2 shared papers, 2021–2022 · strength 0.30
  21. Ryan Blair O'Malley · 2 shared papers, 2021–2022 · strength 0.30
  22. Gabriela R. Rossi · 3 shared papers, 2016–2022 · strength 0.26
  23. Thomas J. George · 2 shared papers, 2022–2023 · strength 0.25
  24. Simon K. Lo · 1 shared paper, 2026 · strength 0.25
  25. Abrahm Levi · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.